[Molecular medicine in asthma].
Ohta
Ken
K
Division of Respiratory Medicine and Allergology, Department of Medicine, Teikyo University School of Medicine.
D000818:Animals; D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001249:Asthma / Q000209:etiology* / Q000473:pathology / Q000628:therapy; D001980:Bronchi / Q000473:pathology; D018925:Chemokines / Q000502:physiology; D016207:Cytokines / Q000502:physiology; D004804:Eosinophils / Q000502:physiology; D005355:Fibrosis; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D007167:Immunotherapy; D018664:Interleukin-12 / Q000627:therapeutic use; D008407:Mast Cells / Q000502:physiology; D009130:Muscle, Smooth / Q000473:pathology; D009504:Neutrophils / Q000502:physiology; D000069444:Omalizumab; D019948:Receptors, Interleukin-4 / Q000627:therapeutic use
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018925:Chemokines; D016207:Cytokines; D019948:Receptors, Interleukin-4; D018664:Interleukin-12; D000069444:Omalizumab; D007073:Immunoglobulin E